{"id":"https://openalex.org/W4401435211","doi":"https://doi.org/10.1111/bcp.16194","title":"Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1","display_name":"Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1","publication_year":2024,"publication_date":"2024-08-07","ids":{"openalex":"https://openalex.org/W4401435211","doi":"https://doi.org/10.1111/bcp.16194","pmid":"https://pubmed.ncbi.nlm.nih.gov/39113219","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11602945"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.16194","doi":"https://doi.org/10.1111/bcp.16194","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.16194","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.16194","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.16194","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Steven Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210143007","display_name":"Dicerna Pharmaceuticals (United States)","ror":"https://ror.org/03qcf9t82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210143007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Steven Zhang","raw_affiliation_strings":["Dicerna Pharmaceuticals, Inc. a Novo Nordisk company, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dicerna Pharmaceuticals, Inc. a Novo Nordisk company, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I4210143007"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001434339","display_name":"Aniruddha C. Amrite","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aniruddha Amrite","raw_affiliation_strings":["Pyxis Oncology, Boston, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pyxis Oncology, Boston, Massachusetts, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108552318","display_name":"Beesan Tan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210155505","display_name":"BioNTech (United States)","ror":"https://ror.org/052htmq47","country_code":"US","type":"company","lineage":["https://openalex.org/I4210134778","https://openalex.org/I4210155505"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beesan Tan","raw_affiliation_strings":["BioNTech US Inc., Cambridge, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNTech US Inc., Cambridge, Massachusetts, USA","institution_ids":["https://openalex.org/I4210155505"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109847838","display_name":"Kris M. Jamsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kris Jamsen","raw_affiliation_strings":["Parexel International, Brisbane, Queensland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parexel International, Brisbane, Queensland, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037203487","display_name":"Sudeep Pradhan","orcid":"https://orcid.org/0000-0003-0739-1326","observed_orcids":["https://orcid.org/0000-0003-0739-1326"]},"institutions":[{"id":"https://openalex.org/I4210124468","display_name":"PAREXEL International (United States)","ror":"https://ror.org/02vkbzw76","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124468"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudeep Pradhan","raw_affiliation_strings":["Parexel International, Brisbane, Queensland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Parexel International, Brisbane, Queensland, USA","institution_ids":["https://openalex.org/I4210124468"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113326655","display_name":"Steve Choy","orcid":"https://orcid.org/0009-0002-5385-4096","observed_orcids":["https://orcid.org/0009-0002-5385-4096"]},"institutions":[{"id":"https://openalex.org/I4210160255","display_name":"Boehringer Ingelheim (United States)","ror":"https://ror.org/05kffp613","country_code":"US","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210160255"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steve Choy","raw_affiliation_strings":["Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA","institution_ids":["https://openalex.org/I4210160255"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5085081701","display_name":"Horacio Plotkin","orcid":"https://orcid.org/0000-0001-9216-2135","observed_orcids":["https://orcid.org/0000-0001-9216-2135"]},"institutions":[{"id":"https://openalex.org/I4210143007","display_name":"Dicerna Pharmaceuticals (United States)","ror":"https://ror.org/03qcf9t82","country_code":"US","type":"company","lineage":["https://openalex.org/I4210143007"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Horacio Plotkin","raw_affiliation_strings":["Dicerna Pharmaceuticals, Inc. a Novo Nordisk company, Lexington, Massachusetts, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dicerna Pharmaceuticals, Inc. a Novo Nordisk company, Lexington, Massachusetts, USA","institution_ids":["https://openalex.org/I4210143007"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210143007"],"apc_list":{"value":4550,"currency":"USD","value_usd":4550},"apc_paid":{"value":4550,"currency":"USD","value_usd":4550},"fwci":1.1909,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.78901762,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":97},"biblio":{"volume":"90","issue":"12","first_page":"3176","last_page":"3189"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10606","display_name":"Kidney Stones and Urolithiasis Treatments","score":0.5512999892234802,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10606","display_name":"Kidney Stones and Urolithiasis Treatments","score":0.5512999892234802,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.37450000643730164,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.012799999676644802,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/primary-hyperoxaluria-type-1","display_name":"primary hyperoxaluria type 1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/primary-hyperoxaluria-type-2","display_name":"primary hyperoxaluria type 2","score":0.8889999985694885},{"id":"https://openalex.org/keywords/urinary-oxalate","display_name":"urinary oxalate","score":0.8859999775886536},{"id":"https://openalex.org/keywords/indirect-response-model","display_name":"indirect response model","score":0.7519999742507935},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.7979999780654907},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate","display_name":"estimated glomerular filtration rate","score":0.8119999766349792},{"id":"https://openalex.org/keywords/children-and-adolescents","display_name":"children and adolescents","score":0.6150000095367432},{"id":"https://openalex.org/keywords/two-compartment-model","display_name":"two-compartment model","score":0.5830000042915344}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7522811889648438},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6932991743087769},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.6577073931694031},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6261192560195923},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6147558689117432},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6011413335800171},{"id":"https://openalex.org/C2776239304","wikidata":"https://www.wikidata.org/wiki/Q6954915","display_name":"NONMEM","level":3,"score":0.5768970251083374},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.46605050563812256},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.38423818349838257},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3570263981819153},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003198","descriptor_name":"Computer Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005919","descriptor_name":"Glomerular Filtration Rate","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006960","descriptor_name":"Hyperoxaluria, Primary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010070","descriptor_name":"Oxalates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010070","descriptor_name":"Oxalates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010070","descriptor_name":"Oxalates","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/bcp.16194","doi":"https://doi.org/10.1111/bcp.16194","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.16194","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.16194","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11602945","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11602945","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11602945/pdf/BCP-90-3176.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Clin Pharmacol","raw_type":"Text"},{"id":"pmid:39113219","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39113219","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/bcp.16194","doi":"https://doi.org/10.1111/bcp.16194","is_oa":true,"landing_page_url":"https://doi.org/10.1111/bcp.16194","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.16194","source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4401435211.pdf","grobid_xml":"https://content.openalex.org/works/W4401435211.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1963166481","https://openalex.org/W1963912010","https://openalex.org/W2027702120","https://openalex.org/W2036744553","https://openalex.org/W2041736283","https://openalex.org/W2047038134","https://openalex.org/W2072848717","https://openalex.org/W2083929656","https://openalex.org/W2098725018","https://openalex.org/W2109644074","https://openalex.org/W2336704411","https://openalex.org/W2792467716","https://openalex.org/W2808089905","https://openalex.org/W2943040154","https://openalex.org/W2971422698","https://openalex.org/W3036363721","https://openalex.org/W3126841208","https://openalex.org/W3127624578","https://openalex.org/W3151149834","https://openalex.org/W3197311283","https://openalex.org/W3211882053","https://openalex.org/W4200224342","https://openalex.org/W4232800275","https://openalex.org/W4238135248","https://openalex.org/W4238685196","https://openalex.org/W4254708269","https://openalex.org/W4282832876","https://openalex.org/W4283078409","https://openalex.org/W4292559741","https://openalex.org/W4296573022","https://openalex.org/W4313535453","https://openalex.org/W4367310648","https://openalex.org/W4386046840"],"related_works":["https://openalex.org/W4411960774","https://openalex.org/W3197311283","https://openalex.org/W4386046840","https://openalex.org/W4292559741","https://openalex.org/W4406887879","https://openalex.org/W4416880251","https://openalex.org/W4240476232","https://openalex.org/W4403812142","https://openalex.org/W4397047766","https://openalex.org/W4408861728"],"abstract_inverted_index":{"Abstract":[0],"Aim":[1],"To":[2],"characterize":[3,36],"pharmacokinetic":[4,28],"and":[5,21,42,64,79,82,101,104,112,128,153,165,180,212,238],"pharmacodynamic":[6],"profiles":[7],"of":[8,40,52,148,159,177,214],"nedosiran":[9,41,110,149,236,243],"in":[10,59,61,151,171,205,246],"patients":[11,186,216,248],"with":[12,66,97,157,175,187,252],"primary":[13],"hyperoxaluria":[14],"type":[15],"1":[16],"(PH1),":[17],"identify":[18],"influential":[19,134],"covariates":[20,135],"confirm":[22],"therapeutic":[23],"doses.":[24],"Methods":[25],"A":[26],"population":[27],"(PK)/pharmacodynamic":[29],"(PD)":[30],"(POP\u2010PKPD)":[31],"model":[32,96,233],"was":[33,91,114],"developed":[34],"to":[35,54],"the":[37,43,137,197,201],"concentration\u2010time":[38],"course":[39],"corresponding":[44],"effect":[45],"on":[46],"24\u2010h":[47],"urinary":[48],"oxalate":[49],"(Uox).":[50],"Simulations":[51,241],"dosing":[53,146,199,244],"achieve":[55],"clinically":[56],"meaningful":[57],"reduction":[58],"Uox":[60,113,223,239],"children,":[62],"adolescents":[63,152],"adults":[65,154],"PH1":[67,87,158,176,185,215,247],"were":[68,131,208],"performed.":[69],"Results":[70],"Analyses":[71],"included":[72],"PK":[73,90,206,237],"data":[74,84],"from":[75,85],"143":[76],"healthy":[77],"participants":[78],"PH1/PH2":[80],"patients,":[81],"PD":[83],"46":[86],"patients.":[88],"Nedosiran":[89],"described":[92,115],"by":[93,116,226],"a":[94,144],"two\u2010compartment":[95],"dual":[98],"n\u2010transit":[99],"absorption":[100],"parallel":[102],"linear":[103],"nonlinear":[105],"elimination.":[106],"The":[107,140,230],"relationship":[108],"between":[109],"exposure":[111],"an":[117],"indirect":[118],"response":[119],"model.":[120,139],"Body":[121],"weight,":[122],"estimated":[123],"glomerular":[124],"filtration":[125],"rate":[126],"(eGFR)":[127],"disease":[129],"status":[130],"identified":[132],"as":[133],"for":[136,184],"POP\u2010PK":[138],"simulation":[141],"results":[142],"supported":[143],"weight\u2010banded":[145],"regimen":[147],"sodium":[150],"(\u226512":[155],"years)":[156,174],"170":[160],"mg":[161,167],"(weight":[162,168],"\u226550":[163],"kg)":[164],"136":[166],"<50":[169],"kg),":[170],"children":[172],"(6\u201011":[173],"3.5":[178],"mg/kg,":[179],"no":[181],"dose":[182],"adjustments":[183],"relatively":[188,253],"preserved":[189,254],"kidney":[190,255],"function":[191],"(eGFR":[192],"\u2265":[193],"30":[194],"mL/min/1.73m2).":[195],"Following":[196],"proposed":[198],"regimens,":[200],"simulated":[202],"median":[203],"fold\u2010changes":[204],"AUC0\u2010\u03c4,ss":[207],"acceptable":[209],"(\u22641.51":[210],"fold\u2010change)":[211],"~71%":[213],"across":[217],"all":[218],"age":[219],"groups":[220],"achieved":[221],"near\u2010normal":[222],"(<0.6":[224],"mmol)":[225],"week":[227],"52.":[228],"Conclusions":[229],"final":[231],"POP\u2010PKPD":[232],"characterizes":[234],"observed":[235],"data.":[240],"support":[242],"regimens":[245],"aged":[249],"\u22656":[250],"years":[251],"function.":[256]},"counts_by_year":[{"year":2025,"cited_by_count":3}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2024-08-09T00:00:00"}